Clinical trials: Relapsed
Multiple Sclerosis, Relapsing-Remitting
Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
The purpose of this study is to determine if natalizumab in combination with Glatiramer Acetate (GA) is safe and effective in delaying progression of individuals diagnosed with relapsing-remitting Multiple Sclerosis (MS).
- Trial name
- NCT00097760
- Testing
- Natalizumab
- Volunteers
- 110 people
- Sponsor
- Biogen
Multiple Myeloma
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT05007418
- Testing
- STI-1492
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sorrento Therapeutics, Inc.
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
This is a multicenter, open-label, Phase 2 study to assess the efficacy and safety of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) with EZH2 gene mutation.
- Trial name
- NCT03456726
- Testing
- Tazemetostat
- Where
- 28 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Eisai Co., Ltd.
Relapsed or Refractory Peripheral T-Cell Lymphoma
A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T cell lymphoma.
- Trial name
- NCT04108325
- Testing
- YY-20394
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
This clinical study examined the safety and efficacy of the combination of zanubrutinib and obinutuzumab versus obinutuzumab alone in adults with follicular lymphoma whose disease returned after or did not respond to prior…
- Trial name
- ROSEWOOD (NCT03332017)
- Testing
- Zanubrutinib, Obinutuzumab
- Where
- 88 sites in United States, Australia and 15 more
- Volunteers
- 217 people
- Sponsor
- BeiGene
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
The goal of this clinical trial was to evaluate whether zanubrutinib can effectively treat adults with CD79B-mutant relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT05068440
- Testing
- Zanubrutinib
- Where
- 25 sites in China
- Volunteers
- 65 people
- Sponsor
- BeiGene
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a…
- Trial name
- FIRCE-1 (NCT05972720)
- Testing
- Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
- Where
- 31 sites in United States
- Volunteers
- 101 people
- Sponsor
- CARGO Therapeutics
Leukemia
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
This is a phase I/II, open-label, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in R/R B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT05309213
- Testing
- IM19 CAR-T cells
- Volunteers
- 58 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Chronic Graft-Versus-Host Disease
A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease
Open-label, dose escalation study to evaluate safety, tolerability pharmacokinetic and pharmacodynamic activity, and efficacy of Adrixetinib (Q702) in subjects with relapsed or refractory active chronic graft-versus-host disease…
- Trial name
- NCT07138196
- Testing
- Adrixetinib
- Where
- 8 sites in Spain
- Volunteers
- 18 people
- Sponsor
- Qurient Co., Ltd.
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion…
- Trial name
- NCT07084896
- Testing
- Belantamab mafodotin, Nirogacestat
- Where
- 29 sites in United States, Australia and 11 more
- Volunteers
- 106 people
- Sponsor
- GlaxoSmithKline
Schizophrenia
A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia
The objective of this study is to evaluate the efficacy and safety of cariprazine relative to placebo in the prevention of relapse of symptoms in participants with schizophrenia.
- Trial name
- NCT01412060
- Testing
- Cariprazine
- Where
- 73 sites in United States, India and 3 more
- Volunteers
- 765 people
- Sponsor
- Forest Laboratories
Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ME-401 in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell Non-Hodgkin's Lymphoma and to continue…
- Trial name
- NCT03985189
- Testing
- ME-401
- Where
- 9 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
open-label trial of an allogeneic dual-target CAR-NK product directed against GPC3 and B7-H3 for adults with advanced hepatocellular carcinoma.
- Trial name
- DUET-HCC (NCT07500220)
- Testing
- EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Biotech
Peripheral T-cell Lymphoma
Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Primary Determine the efficacy of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) Secondary Determine the safety…
- Trial name
- PROPEL (NCT00364923)
- Testing
- Pralatrexate Injection
- Where
- 32 sites in United States, Belgium and 4 more
- Volunteers
- 115 people
- Sponsor
- Acrotech Biopharma Inc.
Relapsed/Refractory Multiple Myeloma (RRMM)
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.
- Trial name
- REALiTEC/TAL (NCT06285318)
- Testing
- Teclistamab, Talquetamab
- Where
- 68 sites in Denmark, France and 9 more
- Volunteers
- 900 people
- Sponsor
- Janssen-Cilag Ltd.
Multiple Myeloma Refractory
BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma
This study is a single-arm, multicenter clinical trial of dose escalation and dose expansion.
- Trial name
- NCT07196124
- Testing
- BCMA/GPRC5D CAR-T
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Idiopathic Thrombocytopenic Purpura
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
This single arm study will evaluate the efficacy and safety of MabThera monotherapy in patients with refractory, relapsing or chronic idiopathic thrombocytopenic purpura (ITP).
- Trial name
- NCT00475423
- Testing
- rituximab [MabThera/Rituxan]
- Where
- 12 sites in Australia
- Volunteers
- 122 people
- Sponsor
- Hoffmann-La Roche
Bone Marrow Failure Syndromes, Aplastic Anemias
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes
This is a multicenter, open-label, Phase 1/2 basket study to evaluate the safety and efficacy of Dibotatug (DR-01) in adults with Bone Marrow Failure syndromes.
- Conditions
- Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse
- Trial name
- BMF (NCT07712562)
- Testing
- Dibotatug (DR-01)
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dren Bio
Lymphoma, Mantle-Cell
A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma
The purpose of this study is to investigate and characterize the association of lenalidomide with tumor flare reaction and high tumor burden in participants with relapsed or refractory mantle cell lymphoma.
- Trial name
- NCT03647124
- Testing
- Lenalidomide
- Where
- 79 sites in Austria, France and 5 more
- Volunteers
- 105 people
- Sponsor
- Celgene
Lymphoma
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)
A dose-escalation study to estimate the maximum tolerated dose(MTD) of CAT-8015 that can be safely administered to a patient.
- Trial name
- NCT00587015
- Testing
- CAT-8015
- Where
- 3 sites in United States, Poland
- Volunteers
- 50 people
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.